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RESPONSE TO LETTER
Reply to Letter: “Tumor
Regression After
Neoadjuvant
Chemotherapy in Gastric
Carcinoma: Are There Really
So Few Responders?”
Reply:
W e thank Rausei et al for their com-ments regarding our manuscript.1 We
are pleased to comment on this letter and
to present the results of additional analyses,
which we performed according to their rec-
ommendations.
First of all, we would like to point out
that the prognostic value of the tumor regres-
sion grade was highly significant in univari-
ate analysis, which included all tumor regres-
sion grades (TRGs) and not grouped TRG1a
and TGR1b versus TRG2 and TRG3. We
then decided to compare TRG1a and TRG1b
(complete regression; <10% residual tumor)
versus TRG2 and TRG3 (11%–50% residual
tumor; >50% residual tumor) because this
simplified discrimination revealed the most
significant value in multivariate analysis. Ac-
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cording to Rausei’s recommendation, we now
tested whether the TRG2 group alone showed
a better survival than the TRG3 group, and be-
sides the prolonged median survival (40.1 vs
23.5 months), we could observe a statistically
significant difference (P = 0.02; log-rank
test). We would like to thank Rausei et al for
this valuable remark and are happy to provide
this additional important finding in this reply.
It is correct that we could not show
data about postoperative chemotherapy be-
cause in our case collection the multimodal
treatment consisted of a purely neoadjuvant
chemotherapy followed by surgery. However,
we addressed the question of whether it may
be possible to identify patients who may ben-
efit from adjuvant therapy in a subsequent
work. We agree that discrimination into re-
sponders and nonresponders may be oversim-
plifying in terms of estimation of prognosis.
For that purpose, we have developed a 3-tiered
prognostic score (PRSC), which consists of
the most relevant factors: UICC (Union in-
ternationale contre le cancer) ypT category,
UICCypN category, andTRG. In this context,
TRG2 was considered to have an intermedi-
ate risk score between TRG1 and TRG3. We
could demonstrate that this combined PRSC
can accurately identify 3 groups of gastric
carcinoma patients with significantly differ-
ent outcome after neoadjuvant chemotherapy
and surgery. This article has recently been
published in Annals of Surgery.2
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